Výsledky vyhledávání - "Silvia Massacese"

Akademický článek

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

Autor: Gemma Bruera, Silvia Massacese, Francesco Pepe, Umberto Malapelle, Antonella Dal Mas, Eugenio Ciacco, Giuseppe Calvisi, Giancarlo Troncone, Maurizio Simmaco, Enrico Ricevuto

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 11 (2019)

Background: Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line RAS wild-type and th

Externí odkaz: https://doaj.org/article/22f2f413aa674d4985f539b6f7f03b0d

Zobrazit plný text záznamu

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

Autor: Giuseppe Calvisi, Eugenio Ciacco, Silvia Massacese, Francesco Pepe, Giancarlo Troncone, Enrico Ricevuto, Maurizio Simmaco, Umberto Malapelle, Gemma Bruera, Antonella Dal Mas

Publikováno v: Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 11 (2019)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::237fb6f001752d4c2ef46d8486a8cdfb
http://europepmc.org/articles/PMC6535746

Zobrazit plný text záznamu

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer

Autor: Gemma Bruera, Silvia Massacese, Eugenio Ciacco, Enrico Ricevuto, Antonio Galvano, Antonio Russo, Stefano Guadagni, Giuseppe Calvisi, Antonella Dal Mas

Publikováno v: Oncotarget

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Antonio Galvano 4 , Antonella Dal Mas 5 , Stefano Guadagni 6, 2 , Giuseppe Calvisi 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 , on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncolog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0dda59724272126b2ef2613a68fc126
https://pubmed.ncbi.nlm.nih.gov/29755655

Zobrazit plný text záznamu

Intensive first-line triplet chemotherapy plus cetuximab FIr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

Autor: Enrico Ricevuto, Giuseppe Calvisi, Corrado Ficorella, Gemma Bruera, Eugenio Ciacco, Silvia Massacese, Maurizio Simmaco, Antonella Dal Mas

673 Background: Intensive first line bevacizumab added to triplet, and cetuximab (CET) to doublet in RAS wild-type MCRC significantly increased outcomes. We investigated safety/activity of FIr-C/FOx-C adding CET to triplet in RAS wild-type. Methods:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ccd2636b407b60fa6ef385808f1b838
http://hdl.handle.net/11697/146613

Zobrazit plný text záznamu

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers

Autor: Eugenio Ciacco, Francesco Pepe, Enrico Ricevuto, Silvia Massacese, Piero Marchetti, Gemma Bruera, A. Dal Mas, Maurizio Simmaco, Umberto Malapelle, Giuseppe Calvisi, G. Troncone

Publikováno v: Annals of Oncology. 29:v57

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc829af934a895f37a0e21dab8e2c0ec
https://doi.org/10.1093/annonc/mdy151.205

Zobrazit plný text záznamu

Real life triplet FIr/FOx chemotherapy in first line metastatic pancreatic ductal adenocarcinoma: Recommended schedule for expected activity and safety and phase II study

Autor: R. Manetta, Enrico Ricevuto, Gemma Bruera, S. Carducci, Eugenio Ciacco, Aldo Victor Giordano, Silvia Massacese

Publikováno v: Annals of Oncology. 29:v43

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::293eea92ad796b8ea8d16e63839f2075
https://doi.org/10.1093/annonc/mdy151.153

Zobrazit plný text záznamu

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

Autor: Antonella Dal Mas, Giancarlo Troncone, Silvia Massacese, Gemma Bruera, Enrico Ricevuto, Maurizio Simmaco, Giuseppe Calvisi, Eugenio Ciacco, Umberto Malapelle, Paolo Marchetti, Francesco Pepe

Publikováno v: Journal of Clinical Oncology. 36:e15517-e15517

e15517Background: Intensive triplet chemotherapy/bevacizumab significantly increased MCRC outcome. Phase II study investigated safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line R...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8194add475447bfaf0a8c9e4c772e88e
https://doi.org/10.1200/jco.2018.36.15_suppl.e15517

Zobrazit plný text záznamu

Abstract A052: Predictive wild-type RAS/BRAF and pharmacogenetic biomarkers drive selection of metastatic colorectal cancer patients fit for intensive first-line FIr-C/FOx-C schedule adding cetuximab to triplet chemotherapy

Autor: Giuseppe Calvisi, Gemma Bruera, Maurizio Simmaco, Antonella Dal Mas, Corrado Ficorella, Enrico Ricevuto, Silvia Massacese, Eugenio Ciacco

Publikováno v: Molecular Cancer Therapeutics. 17:A052-A052

Background: Intensive-first line bevacizumab (BEV) addition to triplet chemotherapy significantly increased clinical outcome in metastatic colorectal cancer (MCRC) patients. Cetuximab (CET) addition to doublet chemotherapy significantly increased cli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eafb9890fd6322d2bbce42b551dc39ee
https://doi.org/10.1158/1535-7163.targ-17-a052

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání